Mariëtte Labots

The many faces of atrioventricular block in myocarditis: a case series and proposed clinical strategy highlighting cardiovascular magnetic resonance–guided diagnosis, device selection, and disease monitoring

Michiel J. Bom, Luuk H G A Hopman, Vokko P. van Halm, Suzan F M Nijman et autres

nl (code pays fourni par la source)

Goal disturbance and emotional symptoms in patients with cancer

G. Elise Doppenberg-Smit, Myra E. van Linde, Femke Lamers, Annemarie Braamse et autres

nl (code pays fourni par la source)

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Tristan V.M. Bruijn, Alexandre Gérard, Maëlys Labat, Zoé Apalla et autres

nl, fr, gr, gb, us, es (code pays fourni par la source)

Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma

Jessica C.L. Notohardjo, Elisa C. Toffoli, Tara Muijlwijk, Mari F.C.M. van den Hout et autres

us, hr, nl (code pays fourni par la source)

Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?

Marije Strikwerda, Lotte Hoeijmakers, Sophie P G R Veenstra, Alfons J M Van Den Eertwegh et autres

nl, it (code pays fourni par la source)

CMAS dampens anti-tumor immunity and associates with response to neoadjuvant immunotherapy in melanoma

Magali Coccimiglio, Sofia Ibáñez‐Molero, Babet Olivia Springer, Laura Goossens-Kruijssen et autres

nl, it (code pays fourni par la source)

Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer

Frits I. Mulder, Noori A.M. Guman, Job van Riet, Roos J. van Geffen et autres

us, nl, de (code pays fourni par la source)

Immune checkpoint inhibitor myocarditis: when profound troponin elevation diverges from unremarkable imaging

Roel S Driessen, P Stefan Biesbroek, Philippe J. van Rosendael, Jeroen Slaats et autres

nl, us (code pays fourni par la source)

Supplementary Data S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer

Sophie L. Gerritse, Erik J. van Helden, Anne I.J. Arens, Ronald Boellaard et autres

Supplementary Table S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer

Sophie L. Gerritse, Erik J. van Helden, Anne I.J. Arens, Ronald Boellaard et autres

Data from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer

Sophie L. Gerritse, Erik J. van Helden, Anne I.J. Arens, Ronald Boellaard et autres

Supplementary Figure S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer

Sophie L. Gerritse, Erik J. van Helden, Anne I.J. Arens, Ronald Boellaard et autres